Feb 13, 2022 | Car Problems Car Complaints
Class Action Lawsuit Filed on Behalf of Owners and Lessees of 2022 Mitsubishi Outlander Vehicles
On February 9, 2022, a class action lawsuit was filed in United States District Court, District of Massachusetts, against Mitsubishi Motors North America, Inc. (“Mitsubishi”) on behalf of past and present owners and lessees of defective 2022 Mitsubishi Outlander vehicles, because the vehicles, allegedly, contain defective hoods that flutter and bounce when driving.
According to the class action complaint, the defective hood poses a safety hazard, because a bouncing and fluttering hood distracts drivers concerned that the hood may be become unlatched and open at any moment, thus drawing attention to the hood defect and away from other members of the motoring public and/or pedestrians.
Despite being notified of the hood defect from, among other things, pre-production testing, numerous consumer complaints (both to the NHTSA and on Mitsubishi enthusiast websites) warranty data, and dealership repair orders, Mitsubishi has not, according to the complaint, recalled the subject vehicles to repair the defect and has not offered a suitable repair or replacement hood that is not defective.
OWNERS AND LESSEES OF 2022 MITSUBISHI OUTLANDER VEHICLES WITH A MALFUNCTIONING HOOD ARE ENCOURAGED TO COMPLETE THE FORM ON THE RIGHT OR CONTACT KEHOE LAW FIRM, P.C., [email protected], FOR A FREE, CONFIDENTIAL CONSULTATION AND NO-OBLIGATION EVALUATION OF POTENTIAL LEGAL CLAIMS.
Feb 13, 2022 | Shareholder Investigations
Cortexyme, Inc. Investor Alert – Cortexyme Shareholders Who Have Suffered Losses On Their CRTX Investment Encouraged To Contact Kehoe Law Firm, P.C.
On January 26, 2022, Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) announced that it received a letter from the U.S. Food and Drug Administration (“FDA”) on January 25, 2022, placing a full clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303). The Company also announced the immediate implementation of a cost reduction program to rationalize operations.
On this news, shares of Cortexyme dropped more than 30%, closing at $6.21 per share on January 26, 2022.
Cortexyme also reported that on February 2, 2022, the Company’s Board of Directors approved the previously announced cost reduction program to rationalize operations and to allow continued support for the needs of its business following the clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303). Under the cost reduction program, Cortexyme stated that it is reducing headcount by approximately 53% through a workforce reduction.
Cortexyme Shareholders Who Have Lost Money On Their Investment
Cortexyme investors who have suffered financial losses are encouraged to complete Kehoe Law Firm’s Securities Class Action Questionnaire or contact Kehoe Law Firm, P.C., [email protected], to discuss potential legal claims.
